Free Trial
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free SPEC Stock Alerts

INSPECS Group (SPEC) Competitors

INSPECS Group logo
GBX 83.50 +0.36 (+0.43%)
As of 05/5/2026 11:43 AM Eastern
Compare

SPEC vs. TSTL, BVC, AKR, CNSL, and ODX

Should you be buying INSPECS Group stock or one of its competitors? The main competitors of INSPECS Group include Tristel (TSTL), BATM Advanced Communications (BVC), Akers Biosciences (AKR), Cambridge Nutritional Sciences (CNSL), and Omega Diagnostics Group (ODX). These companies are all part of the "medical instruments & supplies" industry.

How does INSPECS Group compare to Tristel?

INSPECS Group (LON:SPEC) and Tristel (LON:TSTL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability, media sentiment and institutional ownership.

14.8% of INSPECS Group shares are held by institutional investors. Comparatively, 22.5% of Tristel shares are held by institutional investors. 21.0% of INSPECS Group shares are held by company insiders. Comparatively, 21.0% of Tristel shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

INSPECS Group has a beta of 1.674, suggesting that its share price is 67% more volatile than the S&P 500. Comparatively, Tristel has a beta of 0.289, suggesting that its share price is 71% less volatile than the S&P 500.

Tristel has a net margin of 15.88% compared to INSPECS Group's net margin of -4.25%. Tristel's return on equity of 23.64% beat INSPECS Group's return on equity.

Company Net Margins Return on Equity Return on Assets
INSPECS Group-4.25% -8.73% 0.45%
Tristel 15.88%23.64%9.89%

In the previous week, INSPECS Group's average media sentiment score of 0.00 equaled Tristel'saverage media sentiment score.

Company Overall Sentiment
INSPECS Group Neutral
Tristel Neutral

INSPECS Group presently has a consensus price target of GBX 60, indicating a potential downside of 28.14%. Tristel has a consensus price target of GBX 400, indicating a potential downside of 4.95%. Given Tristel's higher probable upside, analysts clearly believe Tristel is more favorable than INSPECS Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
INSPECS Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Tristel
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Tristel has lower revenue, but higher earnings than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than Tristel, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
INSPECS Group£195.28M0.43-£4.11M-£8.06N/A
Tristel£49.54M4.07£6.54M£16.2425.91

Summary

Tristel beats INSPECS Group on 10 of the 14 factors compared between the two stocks.

How does INSPECS Group compare to BATM Advanced Communications?

BATM Advanced Communications (LON:BVC) and INSPECS Group (LON:SPEC) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk, media sentiment and institutional ownership.

BATM Advanced Communications has a beta of 0.725, meaning that its share price is 28% less volatile than the S&P 500. Comparatively, INSPECS Group has a beta of 1.674, meaning that its share price is 67% more volatile than the S&P 500.

BATM Advanced Communications has higher earnings, but lower revenue than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than BATM Advanced Communications, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BATM Advanced Communications£123.20M0.38-£278.26K-£4.20N/A
INSPECS Group£195.28M0.43-£4.11M-£8.06N/A

11.1% of BATM Advanced Communications shares are held by institutional investors. Comparatively, 14.8% of INSPECS Group shares are held by institutional investors. 30.4% of BATM Advanced Communications shares are held by insiders. Comparatively, 21.0% of INSPECS Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

INSPECS Group has a net margin of -4.25% compared to BATM Advanced Communications' net margin of -14.90%. INSPECS Group's return on equity of -8.73% beat BATM Advanced Communications' return on equity.

Company Net Margins Return on Equity Return on Assets
BATM Advanced Communications-14.90% -22.13% 0.58%
INSPECS Group -4.25%-8.73%0.45%

In the previous week, BATM Advanced Communications' average media sentiment score of 0.00 equaled INSPECS Group'saverage media sentiment score.

Company Overall Sentiment
BATM Advanced Communications Neutral
INSPECS Group Neutral

INSPECS Group has a consensus price target of GBX 60, indicating a potential downside of 28.14%. Given INSPECS Group's higher possible upside, analysts clearly believe INSPECS Group is more favorable than BATM Advanced Communications.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BATM Advanced Communications
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
INSPECS Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

INSPECS Group beats BATM Advanced Communications on 7 of the 12 factors compared between the two stocks.

How does INSPECS Group compare to Akers Biosciences?

INSPECS Group (LON:SPEC) and Akers Biosciences (LON:AKR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership.

14.8% of INSPECS Group shares are held by institutional investors. 21.0% of INSPECS Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, INSPECS Group's average media sentiment score of 0.00 equaled Akers Biosciences'average media sentiment score.

Company Overall Sentiment
INSPECS Group Neutral
Akers Biosciences Neutral

Akers Biosciences has a net margin of 0.00% compared to INSPECS Group's net margin of -4.25%. Akers Biosciences' return on equity of 0.00% beat INSPECS Group's return on equity.

Company Net Margins Return on Equity Return on Assets
INSPECS Group-4.25% -8.73% 0.45%
Akers Biosciences N/A N/A N/A

Akers Biosciences has lower revenue, but higher earnings than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than Akers Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
INSPECS Group£195.28M0.43-£4.11M-£8.06N/A
Akers Biosciences£2.32M0.00N/A-£129.60N/A

INSPECS Group currently has a consensus target price of GBX 60, indicating a potential downside of 28.14%. Given Akers Biosciences' higher possible upside, analysts clearly believe Akers Biosciences is more favorable than INSPECS Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
INSPECS Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Akers Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

INSPECS Group beats Akers Biosciences on 7 of the 11 factors compared between the two stocks.

How does INSPECS Group compare to Cambridge Nutritional Sciences?

INSPECS Group (LON:SPEC) and Cambridge Nutritional Sciences (LON:CNSL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability.

In the previous week, INSPECS Group's average media sentiment score of 0.00 equaled Cambridge Nutritional Sciences'average media sentiment score.

Company Overall Sentiment
INSPECS Group Neutral
Cambridge Nutritional Sciences Neutral

INSPECS Group has a beta of 1.674, meaning that its share price is 67% more volatile than the S&P 500. Comparatively, Cambridge Nutritional Sciences has a beta of 2.101, meaning that its share price is 110% more volatile than the S&P 500.

Cambridge Nutritional Sciences has a net margin of 16.94% compared to INSPECS Group's net margin of -4.25%. Cambridge Nutritional Sciences' return on equity of 12.15% beat INSPECS Group's return on equity.

Company Net Margins Return on Equity Return on Assets
INSPECS Group-4.25% -8.73% 0.45%
Cambridge Nutritional Sciences 16.94%12.15%-2.36%

Cambridge Nutritional Sciences has lower revenue, but higher earnings than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than Cambridge Nutritional Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
INSPECS Group£195.28M0.43-£4.11M-£8.06N/A
Cambridge Nutritional Sciences£8.06M0.61-£3.03M£0.603.44

14.8% of INSPECS Group shares are held by institutional investors. Comparatively, 1.6% of Cambridge Nutritional Sciences shares are held by institutional investors. 21.0% of INSPECS Group shares are held by company insiders. Comparatively, 7.8% of Cambridge Nutritional Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

INSPECS Group currently has a consensus target price of GBX 60, suggesting a potential downside of 28.14%. Given INSPECS Group's stronger consensus rating and higher probable upside, research analysts clearly believe INSPECS Group is more favorable than Cambridge Nutritional Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
INSPECS Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Cambridge Nutritional Sciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

INSPECS Group and Cambridge Nutritional Sciences tied by winning 7 of the 14 factors compared between the two stocks.

How does INSPECS Group compare to Omega Diagnostics Group?

INSPECS Group (LON:SPEC) and Omega Diagnostics Group (LON:ODX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership, media sentiment and risk.

Omega Diagnostics Group has lower revenue, but higher earnings than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than Omega Diagnostics Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
INSPECS Group£195.28M0.43-£4.11M-£8.06N/A
Omega Diagnostics Group£7.55M0.00-£3.17M-£0.01N/A

INSPECS Group presently has a consensus target price of GBX 60, suggesting a potential downside of 28.14%. Given Omega Diagnostics Group's higher probable upside, analysts plainly believe Omega Diagnostics Group is more favorable than INSPECS Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
INSPECS Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Omega Diagnostics Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, INSPECS Group's average media sentiment score of 0.00 equaled Omega Diagnostics Group'saverage media sentiment score.

Company Overall Sentiment
INSPECS Group Neutral
Omega Diagnostics Group Neutral

INSPECS Group has a beta of 1.674, meaning that its share price is 67% more volatile than the S&P 500. Comparatively, Omega Diagnostics Group has a beta of 3.85, meaning that its share price is 285% more volatile than the S&P 500.

14.8% of INSPECS Group shares are owned by institutional investors. Comparatively, 29.8% of Omega Diagnostics Group shares are owned by institutional investors. 21.0% of INSPECS Group shares are owned by insiders. Comparatively, 50.6% of Omega Diagnostics Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

INSPECS Group has a net margin of -4.25% compared to Omega Diagnostics Group's net margin of -51.15%. INSPECS Group's return on equity of -8.73% beat Omega Diagnostics Group's return on equity.

Company Net Margins Return on Equity Return on Assets
INSPECS Group-4.25% -8.73% 0.45%
Omega Diagnostics Group -51.15%-29.14%-10.53%

Summary

INSPECS Group beats Omega Diagnostics Group on 7 of the 13 factors compared between the two stocks.

Get INSPECS Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for SPEC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPEC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SPEC vs. The Competition

Export
MetricINSPECS GroupMedical Instruments & Supplies IndustryMedical SectorLON Exchange
Market Cap£84.90M£2.83B£6.25B£2.73B
Dividend Yield2.00%2.00%2.74%6.11%
P/E Ratio-10.3616.6129.24365.27
Price / Sales0.4383.80504.6887,989.37
Price / Cash1.63146.5443.3027.89
Price / Book0.832.359.677.39
Net Income-£4.11M£99.80M£3.55B£5.89B
7 Day Performance0.43%0.73%3.02%1.15%
1 Month Performance1.83%2.63%5.13%5.27%
1 Year Performance119.74%-7.14%38.78%80.15%

INSPECS Group Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SPEC
INSPECS Group
0.5853 of 5 stars		GBX 83.50
+0.4%		GBX 60
-28.1%		+108.8%£84.90M£195.28MN/A1,673
TSTL
Tristel
N/AGBX 404.05
+3.1%		GBX 400
-1.0%		+13.7%£193.67M£49.54M24.88208
BVC
BATM Advanced Communications
0.6104 of 5 stars		GBX 13.80
+2.6%		N/A-4.9%£46.93M£123.20MN/A980
AKR
Akers Biosciences
N/AN/AN/AN/A£21.64M£2.32MN/A120
CNSL
Cambridge Nutritional Sciences
N/AGBX 2.20
+10.0%		N/A-24.9%£5.24M£8.06M3.673,200

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:SPEC) was last updated on 5/6/2026 by MarketBeat.com Staff.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
I’m sounding the alarm
Meta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...
Porter & Company | Sponsoredtc pixel
How to collect $1,170/month from silver
There is a silver fund paying up to 20% in yearly distributions - no mining stocks, no options required. The s...
Investors Alley | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Did you miss The Dark AI Summit?
Over 55,000 people attended Jeff Brown's Dark AI Summit, where he revealed a private AI company he believes ho...
Brownstone Research | Sponsoredtc pixel
Iran War Update: Trump’s Hand-Written Letter Reveals What Comes Next
Jim Rickards has uncovered what he believes is Trump's economic plan, with a key trigger date of May 15. The F...
Paradigm Press | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel